share_log

iBio Inc | 3: Initial statement of beneficial ownership of securities-Officer Banjak Marc

iBio Inc | 3: Initial statement of beneficial ownership of securities-Officer Banjak Marc

iBio Inc | 3：首次持股聲明-高管 Banjak Marc
美股SEC公告 ·  08/15 05:26
牛牛AI助理已提取核心訊息
Marc Banjak, Chief Legal Officer of iBio Inc, filed an Initial Statement of Beneficial Ownership of Securities with the SEC on August 14, 2024. The filing, required under Section 16(a) of the Securities Exchange Act of 1934, details Banjak's direct ownership of non-derivative and derivative securities in the company. The non-derivative securities include 1,875 shares of common stock represented by restricted stock units (RSUs) that vested quarterly over 12 months, with the final tranche vesting on March 31, 2024. Additionally, the filing outlines multiple stock options with varying vesting schedules and exercise prices, including options for 800 shares at $170.4, 600 shares at $141.2, 3,000 shares at $6.92, 29,000 shares at $1.72, and 55,000 shares at $1.88. These options have exercise periods ranging from 2022 to 2034 and are contingent upon Banjak's continued employment with iBio Inc.
Marc Banjak, Chief Legal Officer of iBio Inc, filed an Initial Statement of Beneficial Ownership of Securities with the SEC on August 14, 2024. The filing, required under Section 16(a) of the Securities Exchange Act of 1934, details Banjak's direct ownership of non-derivative and derivative securities in the company. The non-derivative securities include 1,875 shares of common stock represented by restricted stock units (RSUs) that vested quarterly over 12 months, with the final tranche vesting on March 31, 2024. Additionally, the filing outlines multiple stock options with varying vesting schedules and exercise prices, including options for 800 shares at $170.4, 600 shares at $141.2, 3,000 shares at $6.92, 29,000 shares at $1.72, and 55,000 shares at $1.88. These options have exercise periods ranging from 2022 to 2034 and are contingent upon Banjak's continued employment with iBio Inc.
2024年8月14日，ibio inc的首席法律官馬克·班亞克向SEC提交了關於證券利益的初始聲明。根據1934年證券交易法的第16（a）條要求，申報文件詳細說明Banjak在公司所擁有的不可再生和衍生證券方面的直接所有權。其中，不可再生證券包括1875股普通股，由限制性股票單位（RSU）代表，每季度分四次發放，持續12個月，最後一筆將於2024年3月31日發放。此外，申報還概述了多種股票期權，包括不同的解禁計劃和行權價格，包括800股股票以170.4美元、600股股票以141.2美元、3000股股票以6.92美元、29000股股票以1.72美元、以及55000股股票以1.88美元的期權。這些期權的行權期限從2022年到2034年不等，並取決於Banjak在ibio inc的繼續僱傭。
2024年8月14日，ibio inc的首席法律官馬克·班亞克向SEC提交了關於證券利益的初始聲明。根據1934年證券交易法的第16（a）條要求，申報文件詳細說明Banjak在公司所擁有的不可再生和衍生證券方面的直接所有權。其中，不可再生證券包括1875股普通股，由限制性股票單位（RSU）代表，每季度分四次發放，持續12個月，最後一筆將於2024年3月31日發放。此外，申報還概述了多種股票期權，包括不同的解禁計劃和行權價格，包括800股股票以170.4美元、600股股票以141.2美元、3000股股票以6.92美元、29000股股票以1.72美元、以及55000股股票以1.88美元的期權。這些期權的行權期限從2022年到2034年不等，並取決於Banjak在ibio inc的繼續僱傭。
有用
沒用

該公告為獨立文件：

獨立文件1  查看翻譯

譯文內容由第三人軟體翻譯。


牛牛AI助手部分由第三方人工智慧模型基於資訊內容自動產生，只对除中国内地以外的地区提供。


以上內容僅用作資訊或教育之目的，不構成與富途相關的任何投資建議。富途竭力但無法保證上述全部內容的真實性、準確性和原創性。